Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

Boehringer Ingelheim

Status: Completed

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Treatments: Drug: other systemic therapy; Drug: Afatinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04750824

1200-0335

Details and patient eligibility

About

Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults, 18 years of age or older, at the time of diagnosis with any solid tumor.
• Confirmed NRG1 gene fusion in any solid tumor.
• Initiated afatinib or other systemic therapy (in any line of therapy) for treatment of a solid tumor with NRG1 gene fusion on or after 01/01/2017 through 03/31/2020.
• Followed up for ≥3 months after initiation of afatinib or other systemic therapy (unless deceased prior to 3 months of follow-up).

Exclusion criteria

• Treatment with any Tyrosine kinase inhibitor (TKI)/ErbB-directed therapy other than afatinib

Trial design

110 participants in 2 patient groups

All afatinib patients

Treatment:

Drug: Afatinib

All non-afatinib (other systemic therapies)

Treatment:

Drug: other systemic therapy